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 Aortic stenosis is the most common valvular heart disease, with it’s incidence growing in 
developed countries, as the population ages. When it becomes symptomatic it tends to take a 
rapidly progressive course and soon requires intervention in the form of aortic valve replacement. 
If left untreated, mortality rates are as high as 50% within 2 years of symptom onset. Surgical 
replacement of the aortic valve can significantly increase survival in such patients and reduce 
symptoms of the disease. Unfortunately, the existence of many comorbidities are often found in 
such patients and may severely influence the operative risk and outcome of the aortic valve 
replacement surgical procedure, thence many patients are doomed inoperable and unfit for 
surgery.  
 This category of inoperable patients comprises up to 30% of cases of severe symptomatic 
AS. Up until 2002, this group of patients did not have a viable alternative treatment. In 2002, 
however, the first transcatheter aortic valve implantation procedure was performed where the 
valve was introduced to the appropriate position by means of a catheter.  
 Transcatheter aortic valve implantation is now the treatment of choice for high risk and 
inoperable patients with severe symptomatic aortic stenosis. Despite increasing advantages of 
transcatheter aortic valve implantation, however, several important setbacks and complications 
still exist and many improvements to the procedure are possible and necessary. 
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1. AORTIC STENOSIS 
 Aortic stenosis is defined as narrowing of the aortic valve. This narrowing impedes 
the delivery of blood to the aorta with consequent deleterious effects on the heart, both 
structurally and functionally. Aortic stenosis is the most common valvular heart disease, 
with it’s incidence growing in developed countries, as the population ages (1). The most 
important etiopathogenic factor is the age-related progressive calcification of the valve, 
with this group of patients comprising more than 50% of patients with aortic stenosis. 
Remaining cases mostly consist of patients with calcification of a congenital bicuspid aortic 
valve (30 - 40 %) (2). Rheumatic fever, as a cause of aortic stenosis, is nowadays rarely 
seen in the developed world.   
 Aortic stenosis usually take a prolonged, latent course, with years to take before the 
appearance of symptoms. The rate of the appearance of symptoms usually correlates with 
the degree of stenosis, with mild and moderate stenosis usually being asymptomatic. 
Severe aortic stenosis is usually symptomatic, with the cardinal symptoms comprising a 
triad of exertion syncope, anginal chest pain and shortness of breath due to congestive 
heart failure. If left untreated, mortality rates are as high as 50% within 2 years of symptom 
onset (3). 
 
1.1. The Aortic Valve 
 The aortic valve is a semilunar, trileaflet heart valve situated between the left 
ventricle and the aorta. In it’s normal anatomy, it consists of three cusps; namely the left 
posterior valve, right posterior valve and the anterior valve. In 1-2 % of the population, 
however, the aortic valve is found to be consisted of only two leaflets, a condition named 
congenital bicuspid aortic valve.  
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Figure 1. Anatomy of the Aortic Valve 
 
 The aortic valve, like the remaining heart valves, functions as a pressure valve, 
meaning that the state of the valve being opened or closed will depend on the pressure 
gradient between the left ventricle and the aorta. As the pressure within the left ventricle 
rises during the systole, it overcomes the pressure present in the aorta and the valves will 
shut open to allow the blood to flow from the left ventricle into the aorta. During diastole, 
the pressure gradient reverses, and the valve will shut close. The main purpose of the 
aortic valve is to prevent the back-flow of blood from the aorta to the left ventricle during 
diastole, thus ensuring the unidirectional flow of blood. Additionally, the valve contains 
openings for the origins of the coronary arteries to nourish the myocardium. 
 Physiologic values of the surface area of the valve is in the range of 3.0-4.0 cm2. 
 
1.2. Stenosis 
 Degenerative aortic stenosis, the most common variety, as well as the bicuspid 
aortic stenosis, have a common beginning - damage to endothelial cells from increased 
mechanical stress. In calcific AS, the valve cusps become progressively thickened, 
fibrosed, and calcified.  
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 Inflammation is thought to be involved in earlier stages of the pathogenesis of AS 
and its associated risk factors are known to promote the deposition of LDL cholesterol and 
Lipoprotein(A) into the aortic valve resulting in significant damage and stenosis over time 
(3,4). 
Figure 2.  Pathophysiology of Aortic Stenosis 
 
Figure 3. Calcified Aortic Valve in a Patient With Aortic Stenosis 
 
 The normal aortic valve usually has an opening with the cross-sectional surface 
area of approximately 3.0-4.0 cm2. With progression of AS, this surface area diminishes. 
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Surface area of less than 1.0 cmm2  is associated with symptomatic aortic stenosis with 
increasing severity (5).  
 Continuos heart action against increasing resistance exerted by the stenotic valve 
will progressively lead to structural and functional changes within the heart itself. AS 
causes an increase in pressure afterload and ventricular wall stress that stimulates 
hypertrophy of the left ventricular myocardium. Myocytes enlarge and wall thickness 
increases in a response that initially restores wall stress and preserves left ventricular 
function (6,7). However, evidence is accumulating that increasing levels of hypertrophy 
may in fact be maladaptive. The landmark Framingham studies first linked increasing 
hypertrophy with the progression to heart failure, and left ventricular hypertrophy is now 
considered a marker of an adverse prognosis across a number of cardiac conditions, 
including AS (8).  
 
1.3. Diagnosis and Classification of Aortic Stenosis 
 The diagnosis of aortic stenosis is most commonly established during it’s mild, 
asymptomatic stage, as an incidental finding during a routine physical examination. 
Despite the lack of symptoms, certain signs can be detected by the physician, who may 
thereafter question the well-being of the cardiovascular system. Pulsus parvus et tardus, 
apical-carotid delay, ejection click with a split of the first heart sound and, most 
prominently, a pan-systolic ejection murmur (usually described as crescendo-
decrescendo) radiating to the carotid arteries are the most common abnormal findings 
during the physical examination that will cause the physician to order additional work-up 
and try to reveal the root of these abnormalities. 
 Even though electrocardiography does not contain pathognomonic signs of AS, it 
does show some changes that are characteristic but not specific for the disease, if they are 
present. The changes that are more likely to be seen are those indicating left ventricular 
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hypertrophy, a consequence of the increased workload on the left ventricle. Additionally, in 
cases where the calcification progresses and affects the conducting system of the heart, 
these changes can also be detected by ECG in the form of heart blocks such as the left 
bundle branch block. Again, the aforementioned changes are not specific for AS, hence  
additional, more detailed examination of the heart, and visualisation of the chambers, 
valves and heart walls  is necessary (5).  
 Figure 4. ECG Showing Signs of Left Ventricular Hypertrophy in a Patient With Aortic Stenosis 
 
 Echocardiography is used as a non-invasive method for the assessment of the 
heart valves. By determining the velocity of the blood through the valve, the pressure 
gradient across the valve can be calculated by the continuity equation or using the 
modified Bernoulli’s equation. The stenotic aortic valve will significantly elevate the 
pressure gradient and aortic jet velocity. Both trans-thoracic and trans-oesophageal 
echocardiography can be used in the assessment. 
 Heart catheterisation provides a definite diagnosis, but due to it’s invasiveness, it is 
reserved only for those patients where the severity of the stenosis cannot be determined 
by any other means with satisfactory accuracy to guide clinical decision for the choice of 
treatment. When there are discrepancies between the clinical picture presented by the 
patient and echocardiographic findings obtained by the physician, heart catheterisation 
offers means to directly measure the pressures in the left ventricle and the aorta for more 
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precise assessment of the degree of stenosis. Since the values obtained by these method 
are a result of a direct measurement, as opposed to calculated values derived by 
echocardiography, they are used as a basis for further treatment plans and options. 
 The severity of aortic stenosis is assessed by echocardiography. There are three 
main parameters that are used to classify AS into mild, moderate and severe: aortic jet 
velocity,  mean pressure gradient across the aortic valve and the aortic valve surface area.  
Table 1. Classification of Aortic Stenosis 
 
1.4. Treatment 
 In general, pharmacological therapy has relatively poor efficacy in treating aortic 
stenosis (5). Pharmacological therapy is therefore mainly focused on managing and 
treating commonly present coexisting conditions. 
 Hypertension is a high priority in treatment as it is associated with higher mortality 
rates in patients with AS and the occurrence of left heart failure due to its additional load to 
the left ventricle which is already overstressed by the stenotic valve. However, extreme 
caution must be exercised if beta-blockers are to be administered. If angina is present, 
calcium channel blocker and sometimes beta-blockers are used, but nitrates are 
contraindicated due to the possibility of severe hypotension in patients taking nitrates in 
the settings of AS. Heart failure is also treated appropriately, with caution in the choice of 
medicaments.  
 The role of statins in treatment and slowing the progression of AS is still elusive, 
with latest trials not showing significant benefit. There are some studies, however, that are 
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trying to prove the benefit of rosuvastatin in the slowing of progression during the earlier 
phases of AS (9). Regardless, statins are still used for their beneficial effect in prevention 
of ischemic heart disease, an important sequelae of long-standing AS.  
 Eventually, in severe symptomatic AS, patients will require aortic valve 
replacement. For many decades, surgical replacement of the aortic valve was the standard 
of care for all patients with aortic stenosis once they became symptomatic. If left untreated, 
due to it’s progressive nature, aortic stenosis will lead to decompensation, left heart failure 
and, eventually, exitus letalis. 
 
 
 
 
 
 
 
 
Figure 5. Natural Course of Aortic Stenosis 
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2. TRANSCATHETER AORTIC VALVE IMPLANTATION 
 Transcatheter aortic valve implantation (TAVI) is also known as percutaneous aortic 
valve replacement (PAVR), and transcatheter aortic valve replacement (TAVR). 
 In it’s essence, TAVI is a novel procedure for the aortic valve replacement through a 
blood vessel or the chest wall with the use of a catheter to deliver the aortic valve to its 
appropriate position. Several different access points may be used to introduce the 
catheter. Trans-femoral approach uses the femoral artery as an access point for the 
introduction of the catheter. In the Trans-apical approach, a small incision between the ribs 
is made to gain access to the apex of the heart, and the valve is introduced into the 
ventricle transmurally. Trans-subclavian approach is an alternative retrograde pathway 
that has been recently explored where the catheter is introduced into the left subclavian 
artery and retrogradely propagated. This approach is not yet recommended formally. The 
trans-aortic approach involves accessing the aorta through the chest wall. The choice of 
the most appropriate approach depends on several factors that will be described later in 
this text. 
 In 2002, Allen Cribier performed the first human TAVI using an equine valve with a 
balloon-expandable frame. The need for this kind of procedure, as an alternative for 
surgical replacement of the valve, has been long sought, as many patients with AS (up to 
30%) are deemed unfit for surgery. AS is associated with many comorbidities that increase 
the risk from surgery such as CVD and CHF, leading to many patients being excluded 
from the valve replacement program due to high risk of death. Until the introduction of 
TAVI, this group of patients, which represents a significant percentage of total patients with 
AS, did not have a viable alternative for definitive treatment of this life threatening 
condition. Until today, TAVI has been preformed in over 50.000 patients with high 
operative risk and inoperable patients. 
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 In its essence, TAVI procedure for the treatment of advanced aortic stenosis 
consists of three main elements: bioprosthetic valve, a system for visualisation of the valve 
placement to its appropriate position, and the system for the bioprosthetic valve delivery. 
 Replacement of diseased valves with prosthetic heart valves reduces the morbidity 
and mortality associated with native valvular disease, but it comes at the expense of 
risking complications related to the implanted prosthetic device (10). Emergency medicine 
physicians must be able to rapidly identify patients at risk and begin appropriate diagnostic 
testing, stabilisation, and treatment. Even when promptly recognised and treated, acute 
prosthetic valve failure is associated with a high mortality rate. Common complications of 
valve replacement will be described in a later chapter. 
 
2.1. Brief history 
 TAVI has been introduced to history in 2002, in Rouene, France, when Dr. Allen 
Cribier performed the first human transcatheter aortic valve implantation in a patient with 
severe aortic stenosis. In its early days, the progress made was slow, but up-to-date more 
than 50.000 TAVI procedures were preformed in over 40 countries worldwide. 
 Ten years after the initial implantation by Dr. Alain Cribier, TAVI has become an 
established therapy for patients with symptomatic severe aortic stenosis, who are deemed  
to be at too high risk for surgical aortic valve replacement (SAVR). Many reviews have 
described the evolution of the technology and clinical practice over the past decade and 
several key concepts have emerged consequent to data gathered: a collaborative heart 
team, careful patient selection including risk scoring and frailty assessment, and 
development of professional guidelines on clinical practice and outcomes reporting 
(10,11).  
 The requirement of a “heart team” for successful outcomes is highlighted by the 
recent multi-society expert consensus document. The goal is to use a patient-centred 
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approach to determine the optimal treatment method for patients with symptomatic severe 
aortic stenosis. (12,13,14). A heart team usually consist of some or all of the following:  
•  Cardiologist 
•  Interventional cardiologist 
•  Cardiac surgeon 
•  Anaesthesiologist 
•    Radiologist 
  
 The PARTNER trial published in 2011 played a pivotal role in the revolution of 
TAVI, as it was the world’s first randomised, controlled study to test the safety and 
effectiveness of the procedure in people with severe aortic stenosis. Convincing benefits of 
TAVI were proven and since, TAVI became the standard of care for patients 
contraindicated for SAVR (15). 
 Nowadays TAVI is an exciting and rapidly expanding field and offers both clinical 
and quality of life benefits to patients who are considered too sick or at high risk for 
surgery. However, important issues that adversely affect TAVI outcomes remain, and 
careful patient selection and device improvement may help address current challenges. A 
multidisciplinary patient-centred team approach will likely bring a sustained positive impact 
in this population.  
 
2.2. Surgical Risk Assessment  
 The precise evaluation of surgical risk in a specific patient is a complex procedure 
requiring an individualised approach to statistical data from databases containing large 
numbers of procedures. The most widely accepted and validated algorithms available 
today are the EuroSCORE and the STS (Society of Thoracic Score) scores. 
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 The aforementioned algorithms are used to asses the surgical risk by evaluating 
various factors that affect the clinical outcome by assigning values to these factors and 
formulating a final score. Naturally, such algorithms are sometimes prone to 
overestimation or underestimation of the surgical risk, especially in patients that greatly 
deviate from standard representatives.    
 EuroSCORE stands for European System for Cardiac Operative Risk Assessment. 
It is a predictive method for calculating operative mortality rate during or shortly after 
undergoing heart surgery. It was originally presented in Brussels in 1998, and has since 
undergone several reviews. Recently, the national British database was used to test 
EuroSCORE; it outperformed other simple scoring systems and approached Bayesian 
models in discrimination power (16). 
 One of the main advantages of EuroSCORE is its simplicity. If a risk factor is 
present in a patient, a weight or number is assigned. The weights are added to give an 
approximate percent predicted mortality (16). 
 In total, it uses 18 different variables to calculate a final score that is presented as a 
percentage, indicating the probability of lethal outcome during or shortly after the surgery. 
Some of these variables include age, gender, NYHA class, previous cardiac surgery, 
mobility, the presence of chronic lung disease or pulmonary hypertension and others.  
 Figure 6. EuroSCORE Calculator 
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 In the context of TAVI, if the EuroSCORE predicted mortality rate for surgical 
replacement of the aortic valve is 20% or higher, the patient is considered eligible for TAVI 
if no absolute contradictions for TAVI are present. In such patients, it is up to the Heart 
Team to do a detailed assessment of the patient and make clinical decisions concerning 
the treatment plan for that particular patient. 
 The STS Risk Calculator, developed by the Society of Thoracic Surgeons, allows 
the calculation a patients’ risk of mortality. Unlike the EuroSCORE, however, the STS 
score additionally allows for prediction of other morbidities, such as long length of stay and 
renal failure. The Risk Calculator incorporates the STS risk models that are designed to 
serve as statistical tools to account for the impact of patient risk factors on operative 
mortality and morbidity. 
Figure 7. Application of the STS Score 
 
2.3. TAVI Indications and Contraindications 
 When discussing about indications for TAVI, it must be considered that  surgical 
AVR has been established in the 1960s, and has since been the standard of care for 
patients with AS, and has been shown to have good long-term results with improved 
survival, regardless of age. In the ideal candidate, surgical AVR has an estimated 
operative mortality of 4%. Over the decades, numerous studies and reviews were made, 
proving its benefits, and currently, the evidence-based bank of knowledge of SAVR is 
substantially more extensive compared to that for TAVI. Therefore, the choice of 
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candidates for TAVI has several crucial steps. Most importantly, patients must have severe 
aortic stenosis and a formal contraindication for surgical valve replacement. The procedure 
should be offered to patients who have a potential for functional improvement after valve 
replacement. It is not recommended for patients who simply refuse surgery on the basis of 
personal preference.  
 SAVR, on the other hand, despite its proved benefits in suitable patents, remains a 
highly invasive surgery and in combination with other comorbidities which are often 
present in patients with AS frequently does not present as a beneficial option. Therefore,  
TAVI has become an established therapy of choice in the treatment of symptomatic severe 
aortic stenosis in patients deemed too high risk for surgical aortic valve replacement and 
has pushed SAVR completely out of the picture in this group of patients. 
 The key element for establishing whether patients are at high risk for surgery is a 
multidisciplinary clinical judgment, which should be used in association with a more 
quantitative assessment, based on the combination of several scores (for example, 
expected mortality >20% with the EuroSCORE and >10% with STS score). This approach 
allows the team to take into account risk factors that are not covered in scores, but are 
often seen in practice, such as chest radiation, previous aortocoronary bypass with patent 
grafts, porcelain aorta, liver cirrhosis etc (16). 
 In the European Union, TAVI is commercially available, and the procedure is 
performed in patients with severe aortic stenosis who are high-risk surgical candidates 
with a logistic EuroScore of more than 20% and in patients who have a contraindication to 
surgical aortic valve replacement (16,17). 
 Once a patient is considered for transcatheter aortic valve implantation, the 
presence of contraindications is assessed. Contraindications for TAVI include the following 
(17): 
• Surgical aortic valve replacement possible, but patient refused  
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• Mild to moderate aortic stenosis 
• Asymptomatic patients 
• Life expectancy <1 year 
• Aortic annulus <18 or >25mm (balloon-expandable) and <20 or >27mm (self-
expandable). This criterion is subject to change as the range of available device sizes 
changes  
• Bicuspid aortic valve 
• Asymmetric heavy valvular calcification 
• Aortic root > 45mm at the aorto-tubular junction 
• Presence of left ventricular apical thrombus  
Figure 8. Algorithm to Determine the Treatment Options of Patients With Severe AS 
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 Patients with low-flow, low-gradient severe aortic stenosis are a rare, but a 
challenging population to manage given the poor prognosis associated with conservative 
or surgical treatment. TAVI may be a viable alternative (18). Such patients have higher 
logistic Euro-Score and have more comorbidities such as CAD, peripheral vascular 
disease, pulmonary hypertension, and >2+ mitral regurgitation. Despite having improved 
New York Heart Association class symptoms and QoL, they have higher 30-day and 1-
year mortality (12.8% and 36.9% respectively) and major adverse cardiac and 
cerebrovascular events. 
 Even though TAVI can be performed safely in this high-risk population, given the 
significant early and mid-term mortality, very careful selection among low-gradient aortic 
stenosis patients will be necessary to derive any potential long-term benefits (18).  
 
2.4. Implantation approches 
 Several different approaches have been described and used for the access of the 
implantation site. Currently, the trans-femoral approach is the option of choice due to it 
being the least invasive method. However, this approach is not always feasible, and soon 
the need for other approaches appeared for patients that are suitable for TAVI but have 
contraindications for the trans-femoral approach. The explored pathways thus far can be 
divided into two main groups; anterograde and retrograde pathways, in respect to their 
introduction into the ascending aorta (19).  
 It is up to the heart team to choose the most appropriate approach in an 
individualised patient-oriented assessment with careful consideration of the various 
indications and contraindications to each approach separately.  
 TTE, TOE, CT scans and contrast-enhanced CT angiography are required to asses 
the vascular approaches and the choice of the most appropriate introduction site for each 
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patient. This emphasises the need for multidisciplinary consideration and the importance 
of the heart team. 
 
2.4.1. TRANS-FEMORAL APPROACH 
 The trans-femoral approach is a retrograde approach where the catheter is 
introduced through the femoral artery. It is the most commonly used approach, and it has 
several important advantages. The procedure may be preformed purely trans-cutaneously 
in the catheterisation lab under local anaesthesia, or alternatively, the common femoral 
artery may be surgically prepared under local or general anaesthesia in the operating 
theatre. It can be used as long as the vessels are of appropriate diameter, i.e. >6mm and 
vascular closure devices are available. 
 Despite it’s advantages, there are several different limitations to this approach, and 
the contraindications are as follows: 
• Severe calcification of the femoral or iliac arteries 
• Tortuosity of the peripheral or iliac arteries 
• Small diameter of the iliac arteries 
• Previous aorto-femoral bypass 
• Severe angulation of the aorta 
• Severe atheroma of the aorta 
• Coarctation of the aorta 
• Aneurysm of the aorta with protruding mural thrombus 
 
 Furthermore, the trans-femoral approach is sometimes associated with post-
operative vascular complications that include vessel dissections, ruptures and avulsions. 
These complications must be timely and adequately attended in order to avoid 
catastrophic sequelae (20).  
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2.4.2. TRANS-APICAL APPROACH 
 Trans-apical approach is an anterograde approach where the catheter is introduced 
through the left ventricle. The cardiac apex is prepared through a small left anterolateral 
mini-thoracotomy. After the procedure, a chest tube is routinely inserted into the left 
pleura. This approach has several clear advantages. Primarily, peripheral vascular disease 
or previous aortic surgery do not represent contraindications. This approach has also been 
described as more straightforward and steady (21). Additionally, the potential risk for 
calcium dislodgement is diminished.  
Figure 9. The Trans-apical (left) and the Trans-femoral approaches (right) 
 
 This procedure can be performed in the catheterisation lab, hybrid room or the 
operating theatre, under general anaesthesia. A high-quality fluoroscopic imaging is a 
prerequisite.  
 Contraindications for the trans-apical approach include the following: 
• Previous surgery of the left ventricle using a patch  
• Calcified pericardium 
• Severe respiratory insufficiency 
• Non-reachable left ventricular apex 
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 A possible complication of this approach is apical bleeding through the introduction 
site. Main factors affecting the occurrence of apical bleeding are those endogenous to the 
patient (i.e. tissue fragility) or those attributable to the experience of the team performing 
the surgery.  
 
2.4.3. TRANS-AORTIC APPROACH  
 This is another novel retrograde approach proposed for the small group of patients 
that have a concomitant contraindication to both the trans-femoral and trans-apical 
approach. The delivery system is introduced into the ascending aorta through a small J-
shaped hemi-sternotomy and secured with a double-string suture, with the procedure 
thereafter carried on as in the trans-femoral approach (22). Alternatively, a right anterior 
mini-thoracotomy may be performed in order to access the aorta.  
 It is, however, contraindicated in the presence of porcelain aorta. The main setback 
for this approach is the risk of massive postoperative bleeding. 
 
2.4.4. TRANS-SUBCLAVIAN APPROACH 
 Trans-subclavian approach is another retrograde approach for TAVI through a 
surgically exposed left subclavian artery. It is also known as the trans-axillary 
approach.This is a novel, recently introduced approach, but several clear advantages have 
been described. Compared to the trans-femoral approach, the distance from the site of 
introduction to the site of implantation is significantly shorter, with a consequent steadier 
pathway of delivery. Equally important, it can be used regardless of the presence of 
peripheral artery disease or a diseased abdominal aorta, and unlike the trans-apical 
approach, does not require thoracotomy (23).  
 Limitations of this approach include the size of the subclavian artery if it cannot 
withstand a 18F catheter and the presence of a patent internal mammary artery, such as a 
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diseased subclavian artery, in redo coronary surgery which contraindicates this approach 
(23). 
 Currently, however, this approach is still not recommended due to scarcity of clinical 
and evidence-based data favouring this approach over formerly mentioned ones. 
 
2.5. Bioprosthetic Valves used in TAVI 
 Currently, there is an increasing number of transcatheter heart valves (THV) that 
can be found on the market. Depending on the manufacturer, the bioprosthetic valve can 
be self-expandable or balloon-expandable. Balloon- expandable bioprosthetic heart valves 
need to be mounted on a deflated balloon catheter which is then inflated once the valve is 
in the desired position, hence securing the valve to its place. Some of the bioprosthetic 
heart valves have been well studied, such as the Edwards Sapien valve in the PARTNER 
trial, while investigation for others are still ongoing (15). Some of the valves are currently 
recommended for only one mode of approach, while others can be used for multiple 
approaches. 
 The bioprosthetic valve consists of 3 main subunits:  
• a bearing solid structure made of stainless steel, cobalt chromium or nitinol which 
serves as mechanical support to valve placement and in its nature it is a stent  
• the valves themselves, which are usually made of  processed porcine or bovine 
pericardium  
• the covering for the entire structure that offers functional properties such as 
haemodynamics, and resistance to thrombosis that are made similar to those of 
native valves.  
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Figure 10. The 3
rd
 generation Edward Sapien Bioprosthetic Aortic Heart Valve 
 
 The most prominent bioprosthetic heart valves currently encountered on the market 
are the Medtronic CoreValve system, Edwards Sapien XT system, Direct Flow system, 
Sadra Lotus by Boston Scientific, St Jude Medical Portico, but many others. A summary of 
the ongoing trials for new-generation valves is as follows: 
Table 2. Most Commonly Encountered Bioprosthetic Heart Valves 
 
2.6. TAVI Complications 
 Despite advances in TAVI technology and experience, a number of important 
issues impacting outcomes remains unresolved. Additional, it seems that the choice of a 
particular THV plays a role in the incidence of some of these complications.  
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2.6.1. STROKE 
 Stroke represents one of the most significant adverse outcomes of TAVI. There are 
several intertwining factors that play a role in the occurrence of stroke, most prominently 
old age, aortic atherosclerotic burden and the severity of calcification of the aortic valve. 
Factors increasing the risk for stroke that are related to the procedure itself include 
crossing a stiff guidewire across the aortic arch, balloon aortic valvuloplasty and valve 
deployment. According to the results presented by the PARTNER trial, cohort B patients ( 
TAVI vs. medical therapy) who underwent TAVI presented with higher stroke rates than 
those treated medically. This difference was significant and persistent: 13.8% for TAVI vs. 
5.5% for medical therapy at 2 years, P=0.009. Strokes occurring within 30-days of TAVI 
were predominantly ischemic while those occurring afterwards were predominantly 
hemorrhagic. Cohort A  of the PARTNER study ( TAVI vs. SAVR), on the other hand, did 
not show meaningful difference in the post-procedural incidence of stroke up to 2 years, 
but did show a difference in stroke rate within 30 days: 4.6% for TAVI vs. 2.4% for SAVR 
(24). 
 2 hazard phases for neurological events have been identified: early phase events 
that occurred more frequently in TAVI than SAVR, and late phase events that are mainly 
influenced by factors endogenous to the patient and disease related factors (24).  
 Recent large multi-centre series and national registries reported stroke risk ranging 
from 0.6% to 5.0% (25).  A meta-analysis of >10,000 patients in 53 studies further 
confirmed that TAVI results in a reasonable procedural stroke rate of 1.5% and a 30-day 
stroke/TIA rate of 3.3% (26).However, the 30-day mortality in stroke patients was 25.5%, 
3.5 times higher than the overall rate of 8.1%. 
 In order to intervene in the rates of stroke occurrence, several different devices for 
deflection or capture of emboli have been developed and are currently under trial. The 
results are thus far encouraging, but not yet adequately conclusive. 
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 Such devices include the Embol-X (Edwards Lifesciences Inc, CA) filter, 
TriGuardTM embolic deflection device (Keystone Heart Ltd, Israel) and the Claret CE Pro 
(Claret Medical Inc, CA) cerebral protection device (27,28,29). Further refinement of such 
devices represent a huge opportunity for improving survival and diminishing morbidity in 
patients undergoing TAVI. 
 Figure 11. Embol-X Filter  
 
2.6.2. PARAVALVULAR LEAK AND AORTIC REGURGITATION 
 Paravalvular leak (PVL) is proved to be a very important issue and complication of 
TAVI. It might be the single most important aspect of AVR where SAVR shows to be 
significantly more advantageous than TAVI, and there is still much space for progress to 
be made in this area. 
 The main factor influencing the higher rates of PVL in TAVI is attributable to the 
nature and mechanical characteristics of valve mode of implantation. SAVR allows for the 
total excision of the stenotic valve, leaving behind a smooth, non-aberrant aortic annulus 
with no irregular surfaces allowing for placement of the prosthesis with a tight seal 
resulting in no PVL. TAVI, on the other hand, requires the stenotic valve as an anchor for 
placement of the implant, not allowing for furbishing and smoothening the surface which 
therefore results in a significant rate of PVL. 
   23
 SAVR rarely has the problem of paravalvular leak or significant aortic regurgitation 
(AR), and in cases where it is present, immediate surgical correction is mandated. The 
cohort A of the PARTNER trial clearly shows a significantly higher PVL and AR rates 
compared to SAVR, with more than 50%  of TAVI patients showing at least mild PVL 
and/or AR in 2-year follow-up (30). 
 The more concerning aspect of these complications is that even mild PVL and AR 
after TAVI are associated with 10-15% higher mortality rates at 2-years than patients with 
no evidence of PVL or AR. Additionally, another study showed that moderate or severe 
aortic regurgitation is the strongest independent risk factor for all-cause as well as 
cardiovascular mortality (31). Although a majority of patients with mild regurgitation of the 
native aortic valve can remain asymptomatic and tolerate the condition for a long time, for 
unknown reasons TAVI patients do not appear to tolerate even mild PVL or AR.  
 In order to address these concerns, various investigations attempted to determine 
risk factors associated with increased risk for PVL and AR. Currently, the suggested 
factors include several anatomic characteristics, such as asymmetrically calcified cusps, 
large annular size, elliptical annular shape, and calcified LV outflow tract may be 
associated with a higher risk of PVL. An improved implantation technique, particular in TA-
TAVI, may reduce the incidence of PVL (32). 
 Given the significant mortality risk associated with mild or greater PVL or AR after 
TAVI, improvement in deployment strategy and advance in TAVI technology will be 
necessary to address this issue. For now, identifying certain avoidable risk factors and 
pitfalls, as suggested by the above studies, or determining the appropriate THV size by 
MDCT, may be all that can be done to minimise these important side effects of TAVI. 
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2.6.3. HEART BLOCK 
 Several risk factors predispose TAVI patients to new-onset left bundle branch block 
(LBBB) and a subsequent heart block requiring a pacemaker. They include the 
compression of the Bundle of His by the device itself or by a post-procedural localised 
haematoma, procedural factors such as balloon aortic valvuloplasty injuring the conducting 
system, as well as device-related factors such as the continuous radial force exerted by 
the CoreValve and the depth of device implant in the left ventricular outflow tract. Equally 
important, patient related risk factors such as the pre-existing right bundle branch block 
(RBBB) may be a predisposing factor for the development of heart block, especially if new 
onset LBBB occurs (33). Studies have showed that the occurrence of these complications 
may be significantly influenced by the choice of the THV device (33). 
 The incidence of pacemaker implant after SAVR has been 3–8%, and in a recent 
comparison study from among 411 TAVI patients using the Edwards THV and 411 
electrocardiography-matched patients who underwent SAVR,  the new pacemaker implant 
rate was higher in the TAVI group (7.3% vs 3.4% in SAVR, P = 0.014) (34). Despite the 
higher incidence of new onset LBBB, heart block and pacemaker implant among TAVI 
patients, there has been no proven adverse impact on survival. 
 The incidence of heart block requiring a new pacemaker was 3–6% for the Sapien 
valve in the PARTNER trial, and ranged from 4.8% to 18% among institutions, multi-centre 
studies and national databases. However, the incidence was much more variable for 
CoreValve, ranging from 12.1% to 49% (35). 
 
2.6.4. VASCULAR COMPLICATIONS 
 The occurrence of vascular complications in TAVI is attributed to the nature of the 
procedure and it’s transcatheter approach. As mentioned earlier, most important catheter-
related vascular complications include vascular dissection, vascular perforation, and 
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access site haematoma. Rare but more significant potential complications include aortic 
dissection and left ventricle perforation. The most concerning implications of the 
occurrence of vascular complications are the associated higher 30-day and 1-year 
mortality rates (36). Minimal arterial diameter smaller than the external sheath diameter, 
moderate or severe vessel calcification, and peripheral vascular disease are the most 
significant risk factors associated with the occurrence of vascular complications.  
 The PARTNER trial demonstrated that vascular access complications during TAVI 
were associated with decreased survival and were risk factors of late mortality (OR 2.78, 
CI 1.58–4.82, P < 0.001) (30,36). The rate of vascular complications among contemporary 
registries range from 2.0% to 13% and decrease with increasing procedural experience 
(37). Contralateral balloon occlusion technique during delivery sheath removal and 
percutaneous arterial closure have been effective in reducing vascular complications 
following TAVI, with technique failure attributing only to obesity, vessel calcification, small 
vessel diameter, and “high” arterial access (38). A recent review of 986 TAVI patients 
performed with the trans-femoral approach in 5 European centres, with an overall major 
vascular complication rate of 14.2%, showed a majority of complications were due to 
closure device failure in those who had percutaneous access (39). 
 
2.6.5. ATRIAL FIBRILLATION  
 The incidence of new-onset atrial fibrillation  following cardiac surgery ranges from 
10% to 60%, with a higher frequency following valve surgery. Postoperative AF is known 
to be associated with increased hospital stay, stroke, and mortality rate (40). The 
incidence of post-procedural AF was significantly lower in the TAVI compared to the SAVR 
group (6.0% vs 33.7%, P < 0.05). Interestingly, patients in the TAVI group most likely 
developed post-procedural AF within the first 24 hours, compared to SAVR patients who 
most likely developed AF on postoperative day 3 (41). 
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 The adverse impact of AF after TAVI has only recently been identified by a study 
finding chronic AF as an independent predictor of late mortality (>30 days) in a study 
analysing 1262 TAVI patients (42). Prior investigations yielded diverse conclusions, but 
increased left atrial size (≥27 mm/m2) and the trans-apical approach were identified as 
predictive factors, and at 30 days of follow-up, the new-onset AF was associated with 
increased stroke/systemic embolism (13.6% vs 3.2%, P = 0.047) but no increase in 
mortality at 30 days and 12 months (15.9% vs 21.3%, P = 0.58) (43). 
 When discussing atrial fibrillation in the context of TAVI, it needs to be stressed out 
that there have been some conflicting results in studies, namely the ones conducted in 
Canada and Germany. (40,41,42,43). This mandates a greater scale studies on larger 
populations of patients undergoing TAVI to appropriately evaluate the mechanisms of new-
onset AF or conversion from preexisting AF to sinus rhythm after TAVI (12).  
 
2.7. TAVI Procedure 
2.7.1 PRE-PROCEDURE PLANNING 
 Main aspects of the pre-procedure planning were already described in the text 
earlier, in regards to the selection of patients that are candidates for TAVI, and more 
elaborately in regards to the choice of the most appropriate approach for TAVI.  
 In summary, echocardiography is used to confirm the severity of aortic stenosis, 
aortic valve anatomy, and extent of calcification and to evaluate the diameter of the aortic 
annulus, ascending aorta, sinus of Valsalva, the distance of the aortic valve leaflets to 
sinotubular junction, the presence of concomitant severe other valvular disease, and the 
LVEF. 
 CT angiography of the aortic root is used to determine the optimal image orientation 
for valve positioning. Left and right cardiac catheterisation is used to evaluate for 
concomitant coronary artery disease or pulmonary hypertension that may require 
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treatment prior to TAVI. CT angiography of the thoraco-abdominal and ilio-femoral arteries 
is used to evaluate the diameter, tortuosity of the vessels, and calcifications and to plan for 
the access site.  
 
Figure 12. 3D reconstruction of contrast-enhanced CT angiography to assess morphology of femoral arteries 
 
 Patients are pretreated with aspirin (80-325 mg) daily and clopidogrel 300 mg 
loading dose at least one hour prior to the procedure and continued at 75 mg oral daily 
dose. After the procedure, aspirin (at least 80 mg daily) is continued indefinitely, and 
clopidogrel 75 mg daily is continued for 1-6 months. 
 Routing laboratory tests prior to the procedure include complete blood cell (CBC) 
count, international normalised ratio (INR), partial thromboplastin time (PTT), albumin and 
transaminase levels, renal function testing, and 12-lead electrocardiography (ECG). 
Cardiac biomarker levels (ie, CK and CK-MB) are also tested within 48 hours of the 
procedure. 
 To minimise the risk of prosthetic valve infection, prophylactic intravenous antibiotic 
therapy at least 1 hour before the procedure is also recommended. Cefuroxime 750 mg IV 
1 hour pre-procedure is usually administered, and the dose is repeated 6 and 12 hours 
after the procedure. In patients who are allergic to penicillin (or cephalosporins), 
vancomycin may be considered. 
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2.7.2. VALVE IMPLANTATION 
 TAVI is performed in the catheterisation lab, hybrid room or the operating theatre by 
a cardiac surgeon or an interventional cardiologist. At this point, all pre-procedural 
examinations must have been completed, with the assessment of the introduction sight, 
the choice of the appropriate approach technique and the visualisation of the diseased 
valve. The procedure is usually performed in general anaesthesia, but in certain cases 
deep sedation with local anaesthesia to the introduction site can be administered. The 
patient remains in the supine position during the procedure. Cardiopulmonary bypass 
equipment should be easily available in case of complications. The room should also be 
equipped with supplies required to treat vascular and coronary complications. 
 At this point, the heart team has already chosen the approach, the appropriate 
prosthetic heart valve, as well as the catheter size in concordance with the selected 
approach. 
 Depending on the selected approach, the introduction site must be exposed, with 
the exception of the purely percutaneous trans-femoral approach where the catheter is 
introduced directly into the femoral artery through the skin. 
 After surgical exposure of the introduction site, an introducer sheath is inserted into 
the blood vessel. Through the introducer sheath, the guidewire is inserted into the blood 
vessel in a retrograde fashion and guided to the aorta until the stenotic valve is reached, 
and then through the aortic valve into the left ventricle. 
 The imaging methods used to navigate the guidewire (as well as the catheters and 
the prosthetic valve)  are fluoroscopy and angiography - as the primary imaging modality 
during device implantation. Echocardiography is frequently used as an adjunct imaging 
tool.  
 Computed tomography (CT), which is critical in preparing for the procedure, is 
increasingly integrated with intra-procedural imaging. The fusion of images from various 
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modalities is rapidly evolving with 3-dimensional (3D) visualisation of anatomy and 
devices. Fluoroscopy has a large field of view and depicts 3D information on a 2-
dimensional (2D) monitor, whereas echocardiography can show 2D or 3D information that 
limits field of view on mostly 2D monitors. Details of the devices are much better seen on 
radiographic imaging, whereas non-calcified tissues are better visualised by ultrasound. 
 Once the guidewire is fully in place, a catheter with a deflated expandable balloon is 
mounted on the guidewire and delivered all the way to the aortic valve. The balloon is 
positioned to be exactly in the level of the valves.  
 Once properly placed, the balloon is inflated and expanded to widen the opening of 
the valves to allow room for the prosthetic valve. The balloon is then deflated and 
removed. Now another ballon catheter is prepared for the valve delivery. The valve is 
compressed and mounted on the tip of the catheter over the expandable balloon and 
introduced over the guidewire to the position of the aortic valve in the already described 
fashion.  
 Once the compressed valve is visualised to be in the necessary position, the 
balloon is inflated to expand the prosthetic valve and now the new prosthetic aortic valve is 
finally in place. The native heart valve is used as an anchor to the prosthesis, and the 
stent, which is part of the prosthetic valve, will support and secure the artificial valve in 
place. The second catheter and the guidewire are then removed. 
 
Figure 13. Fluoroscopy Showing the THV Before (A) and After (B) balloon expansion 
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Figure 14. Anterograde and Retrograde Delivery of the Bioprosthetic Heart Valve  
 
 The function of the newly placed valve must be assessed and visualised by 
echocardiography. Proper position, mechanical function of the valve, AVA, paravalvular 
leakage, regurgitation, pressures and velocities are assessed. 
 If TAVI is deemed successful, the introduction site may be closed by a closure 
device, and the patient is then transferred into an intensive care unit.  
 The above described procedure, however, may vary significantly from one TAVI to 
another. As mentioned earlier in this text, various different manufacturers produce different 
types of valves that may require different steps in TAVI. Some of the bioprosthetic valves 
currently encountered are self-expandable and therefore do not require to be mounted on 
a balloon catheter.  
 Furthermore, also described earlier in this text, sever different approaches in TAVI 
exist, and depending on the particular approach as well as depending on factors 
endogenous to the patient, different sized catheters are used for native valve expansion 
and THV valve delivery. In the trans-apical approach, the valve is not reached through a 
blood vessel but directly through the heart instead. All these variations further emphasise 
the need for a multidisciplinary patient-oriented Heart Team approach and experience. 
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2.8. TAVI in Croatia 
 The TAVI program is relatively new in Croatia, with the first procedure performed in 
2011. Currently, the program is present in 2 institutions in Croatia, namely the University 
Hospital Dubrava and the University Hospital Centre Zagreb. 
 By 2014, 87 TAVI procedures were performed, out of which >55% were performed 
in the University Hospital Dubrava, where the program is supervised by a Heart Team 
consisting of a cardiologist, cardiac surgeon and an anaesthesiologist. The team evaluates 
each patient in an individualised approach to asses the eligibility for the procedure, as well 
as the appropriate approach, valve and equipment that should be used (13).   
 All patients had previous TTE, TEE, aortography and CT made, and the procedures 
were performed by a Heart Team. All but one patient underwent general anaesthesia, with 
the one patient that was deeply sedated. 89% of the patients had TAVI performed by the 
trans-femoral approach, 39% out of which the artery was surgically prepared. 
 The average echocardiography findings prior to and after TAVI are represented by 
the following table: 
 
Table 3. Comparison of Echocardiographic Findings Before and After TAVI 
 
 
 Before TAVI After TAVI 
LVEF 50.8 58,8 
AVA 0,60  
Vmax AO 4,76 2,27 
Aortic  regurgitation 1-2 0-1 
Pulmonary pressure 36,8mmHg 31,75mmHg 
Mitral regurgitation 2-3 1-2 
Tricuspid regurgitation 1-2 1 
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 The outcomes of the procedures are summarised in the following table: 
30 d mortal 1y mortal 2y  
mortal 
3y 
mortal 
CVI PV leak AMI PCI 
before 
PCI + 
TAVI 
Pci 
after 
1% 1% 3% 1% 1% 30% 0 40% 0 1 pt  
Table 4. Outcomes 
 
 In conclusion, TAVI is available for patients in Croatia with very high success rates, 
but with certain limitations, most notably the procedural price. The Heart Team has a 
pivotal role in the development of the program with the responsibility of careful patient 
selection and evaluation. 
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3. FOLLOW-UP 
 TAVI is less invasive than traditional AVR – no sternotomy is performed, 
cardiopulmonary bypass (CPB) is not necessary, and patients may be extubated in the 
operating room (OR). Despite its less invasive nature, over the past few years as the 
number of TAVIs have increased, a unique set of postoperative events and complications 
have been identified. While some ICU management issues are shared with patients 
undergoing traditional AVR, TAVI patients are predisposed to ICU concerns that the 
attending specialist needs to recognise and manage appropriately. 
 
3.1. Pre-discharge Follow-Up 
 After the procedure, the patients that underwent TAVI are extubated and transferred 
to the ICU. The patient should be observed with a temporary pacemaker for up to 48 hours 
to monitor for any conduction system abnormalities. If no conduction system disturbances 
are detected, the patient is monitored for an additional 72 hours and then discharged. 
 The patient should continue taking aspirin 80-325 mg daily and clopidogrel 75 mg 
daily for at least 3 months following the procedure. Repeated doses of cefuroxime 750 mg 
IV should be administered at 6 and12h post-procedure. 
 Both trans-thoracic echocardiography (TTE) and trans-oesophageal 
echocardiography (TOE) may be used to evaluate for complications, as needed. The 
complications have been described earlier in the text in the context of complications of 
TAVI. 
 Apart from the earlier mentioned cardiovascular, prosthesis and procedure related 
complications, some of the other potential sequelae of the procedure include postoperative 
delirium, postoperative pain and renal failure. The occurrence of such events should be 
early recognised and treated appropriately. 
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3.2. Post-discharge Follow-Up 
 Once the patient has shown not to have any complications requiring the 
prolongation of pre-discharge care, and the physician is satisfied with the function of the 
prosthetic valve, the patient may be discharged. 
 The patient should continue aspirin therapy indefinitely, but clopidogrel treatment 
may be ceased after 3 months.  
 The physician must schedule follow-up visits at 30 days, 3 months, 6 months and 1 
year after the procedure. Beyond that, the visits may be on annual basis, providing that no 
reasons for concern have been identified by the patient or the physician.  
 In this rapidly expanding era of TAVI where constantly increasing evidence of 
benefit encourage the wide-spread use of TAVI, numerous studies are constantly being 
published in many countries presenting the statistical analysis and meta-analysis of their 
patients at 30 day, 1 year, 2 year and 5 year post-procedure. The results of the relatively 
young program in Croatia have already been summarised earlier in this text.  
 In 2013, a large scale study obtained results from all eligible USA TAVI cases 
(n=7710) from 224 participating registry hospitals following the Edwards Sapien XT device 
commercialisation (November 2011-May 2013). The results of the study show that the 
7710 patients who underwent TAVI included 1559 (20%) cases that were inoperable and 
6151 (80%) cases that were high-risk but operable. The median age was 84 years 
(interquartile range [IQR], 78-88 years); 3783 patients (49%) were women and the median 
STS predicted risk of mortality was 7% (IQR, 5%-11%). At baseline, 2176 patients (75%) 
were either not at all satisfied (1297 patients [45%]) or mostly dissatisfied (879 patients 
[30%]) with their symptom status; 2198 (72%) had a 5-m walk time longer than 6 seconds 
(slow gait speed).  The most common vascular access approach was trans-femoral (4972 
patients [64%]), followed by trans-apical (2197 patients [29%]) and other alternative 
approaches (536 patients [7%]); successful device implantation occurred in 7069 patients 
   35
(92%; 95% CI, 91%-92%). The observed incidence of in-hospital mortality was 5.5% (95% 
CI, 5.0%-6.1%). Other major complications included stroke (2.0%; 95% CI, 1.7%-2.4%), 
dialysis-dependent renal failure (1.9%; 95% CI, 1.6%-2.2%), and major vascular injury 
(6.4%; 95% CI, 5.8%-6.9%). Median hospital stay was 6 days (IQR, 4-10 days), with 4613 
(63%) discharged home. Among patients with available follow-up at 30 days (n=3133), the 
incidence of mortality was 7.6% (95% CI, 6.7%-8.6%) (non-cardiovascular cause, 52%); a 
stroke had occurred in 2.8% (95% CI, 2.3%-3.5%), new dialysis in 2.5% (95% CI, 2.0%-
3.1%), and re-intervention in 0.5% (95% CI, 0.3%-0.8%) (44). 
 A similar study but on a significantly smaller scale was performed in the UK. In this 
study, however, the follow-up was up to 6 years, thus giving insight to a longer term 
survival rate. The study assessed trends in the performance of transcatheter aortic valve 
implantation in the United Kingdom from the first case in 2007 to the end of 2012. A total of 
3980 transcatheter aortic valve implantation procedures were performed. In successive 
years, there was an increase in frequency of impaired left ventricular function, but there 
was no change in Logistic EuroSCORE. Overall 30-day mortality was 6.3%; it was highest 
in the first cohort (2007-2008), after which there were no further significant changes. One-
year survival was 81.7%, falling to 37.3% at 6 years. Discharge by day 5 rose from 16.7% 
in 2007 and 2008 to 28% in 2012.  
 The only multivariate pre-procedural predictor of 30-day mortality was Logistic 
EuroSCORE ≥40. During long-term follow-up, multivariate predictors of mortality were pre-
procedural atrial fibrillation, chronic obstructive pulmonary disease, creatinine >200 
μmol/L, diabetes mellitus, and coronary artery disease. The strongest independent 
procedural predictor of long-term mortality was peri-procedural stroke (hazard ratio=3.00; 
P<0.0001). Non-femoral access and post-procedural aortic regurgitation were also 
significant predictors of adverse outcome (45).  
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4. CONCLUSION 
 SAVR, as the treatment of choice for aortic stenosis has existed since the 1960s. 
The outcome of patients undergoing AVR has been increasing through the decades as 
numerous advances in medicine allowed for increasing quality in surgical techniques, 
medication and peri-procedural events that keep positively influencing the short-term and 
long-term outcomes of these patients. 
 Since, however, up to 30% of patients with severe symptomatic aortic stenosis are 
not considered eligible for surgery, the need for an alternative method for these patients 
culminated with an introduction of a new approach to the replacement of the aortic valve. 
In 2002, the first transcatheter aortic valve implantation procedure was performed, opening 
a new era in interventional cardiology and cardiac surgery. Since 2002, over 50.000 TAVI 
procedures were made in over 40 countries worldwide, offering a new life to a substantial 
number of patients that could not undergo SAVR.  
 TAVI is procedure where a bioprosthetic aortic valve is introduced into the native 
heart valve through the means of a flexible catheter through a blood vessel or the left 
ventricle. The prosthetic valve is set into place and expanded and is immediately thereafter 
functional.  
 All clinical decisions, including patient selection and procedural approach are made 
by a multidisciplinary heart team which plays a pivotal role in TAVI. Once a patient is 
selected and the procedure is made, the patient is followed-up for several days and may 
be discharged as soon as within 6 days after the procedure.  
 TAVI has many advantages over SAVR, but at the same time, there are still many 
disadvantages and concerning issues that need to be refined to maximise the benefits of 
this approach to valve replacement. It is, nonetheless, impressive that a procedure that is 
not older than 13 years is showing to have almost equal results in terms of outcome as a 
procedure that has been used for about 50 years, even more so when stressed that the 
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patients undergoing TAVI are all either at high surgical risk or inoperable - in other words 
in bad conditions and with multiple comorbidities. 
 TAVI is a procedure in an ever expending period of development, and various 
factors influencing the procedure outcome (both those endogenous to the patient and 
those related to the procedure and the equipment) are being identified on daily basis.  
 The advances made in TAVI has been more than impressive thus far, yet still much 
space for further improvements are present which can significantly alter the long-term 
outcomes and complications of the procedure.  
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